Loading...
Loading...
Browse all stories on DeepNewz
VisitJohnson & Johnson's ($JNJ) New Drug Combinations Show Promise in Multiple Myeloma Treatment
Sep 27, 2024, 12:05 PM
Johnson & Johnson's novel combinations of TALVEY® (talquetamab-tgvs) with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) show promising results in treating patients with relapsed or refractory multiple myeloma. The combinations suggest high response rates and durable responses, including in triple-class refractory patients and those with extramedullary disease. These findings indicate potential advancements in treatment options for this challenging condition. The results are significant for Johnson & Johnson ($JNJ) and its partners, including $GMAB.DC and $GMAB.
View original story
Markets
Yes • 50%
No • 50%
Johnson & Johnson press releases and clinical trial registries
No • 50%
Yes • 50%
Publications in major medical journals like The New England Journal of Medicine, The Lancet, or JAMA
No • 50%
Yes • 50%
FDA announcements and press releases
0-5 trials • 25%
More than 15 trials • 25%
11-15 trials • 25%
6-10 trials • 25%
Clinical trial registries and Johnson & Johnson press releases
10%-20% • 25%
More than 30% • 25%
Less than 10% • 25%
20%-30% • 25%
Market analysis reports from firms like IMS Health or EvaluatePharma
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
Johnson & Johnson's financial reports and earnings calls